Tuberculosis (TB) remains a significant public health challenge in Kenya, with the country among East Africa's highest TB burden nations. The disease presents as active infection affecting primarily the lungs (pulmonary TB) but can involve other organs. TB transmission occurs through airborne respiratory droplets when infected individuals cough, sneeze, or speak. The development of effective antituberculosis drugs in the mid-twentieth century transformed TB from a uniformly fatal condition to a curable disease, though access to treatment has remained unequally distributed historically. Colonial and early post-independence periods saw TB recognized as a public health priority, with sanatorium care and drug therapy available primarily to privileged populations.
Kenya's Tuberculosis Control Programme operates within the broader health system, coordinating case detection, treatment, and prevention activities. The National TB Prevalence Survey estimated TB disease burden, informing program planning and resource allocation. Standard TB treatment consists of a six-month course combining four first-line drugs (isoniazid, rifampicin, pyrazinamide, and ethambutol), with directly observed therapy (DOT) ensuring medication adherence. DOTS (Directly Observed Therapy, Short-course) became the standard approach for TB program management, with health workers observing patients taking medications to reduce treatment failure and drug resistance development.
Drug-resistant tuberculosis (DR-TB) has emerged as a major challenge, with some TB strains resistant to isoniazid and rifampicin (multidrug-resistant TB or MDR-TB). These infections require longer, more toxic, and more expensive treatment regimens using second-line drugs. Treatment outcomes from Kenya's first multidrug-resistant TB program showed 76.6 percent treatment success, 14.5 percent deaths, 8.3 percent lost to follow-up, and 0.7 percent treatment failure. HIV co-infection emerged as a significant predictor of poor TB outcomes, with HIV-positive individuals showing substantially higher mortality. Community-based treatment models demonstrated feasibility for managing MDR-TB outside institutional settings, improving treatment access for dispersed populations.
Kenya became the first country to adopt improved child-friendly TB medicines and injection-free regimens for treating drug-resistant TB, reducing side effects and improving treatment tolerability for pediatric patients. Between 2018 and 2022, TB preventive therapy programs enrolled over 700,000 people with latent TB infection on preventive treatment, including people living with HIV, close contacts of TB patients, and other at-risk populations. These efforts aimed to prevent progression of latent infection to active disease, reducing overall TB transmission.
Contemporary TB control efforts emphasize early case detection through community screening, treatment support to ensure completion, and TB/HIV collaborative activities recognizing the overlap between epidemics. Challenges include the ongoing threat of drug-resistant strains, tuberculosis in prisons and urban slums where transmission is accelerated, and complications in monitoring treatment outcomes among mobile populations. Sustained commitment to evidence-based TB control and health system strengthening remain essential for achieving TB elimination targets.
See Also
AIDS Epidemic Kenya Disease Surveillance Kenya Hospital Infrastructure Standards Poverty Urban Slum Health Services Healthcare Policy Evolution
Sources
- https://pubmed.ncbi.nlm.nih.gov/27776588/
- https://pubmed.ncbi.nlm.nih.gov/28225342/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC4536652/
- https://www.health.go.ke/kenyas-use-evidence-based-and-data-driven-interventions-leads-remarkable-progress-tb-control
- https://chskenya.org/wp-content/uploads/2022/04/GUIDELINES-ON-THE-PROGRAMMATIC-MANAGEMENT-OF-TUBERCULOSIS-PREVENTIVE-THERAPY-PMTPT-2020.pdf